RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.